Eisai
OTC:ESALYPharmaTokyo, Japan, Japan · Est. 1941 · 10,000 employees
Eisai is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines across neurology, oncology, and other therapeutic areas.
9
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
10
Indications↗
Distinct diseases across all programs
584
Clinical Trials↗
All sponsored trials (all statuses)
38
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
9 drugs in development
Phase 31
Phase 25
Phase 14
By Therapeutic Area
top 4
Oncology
333%
Immunology
111%
Neurology
111%
Infectious Disease
111%
R&D Momentum
66/100
Pipeline Velocity
30/100
Trial Completion Rate
89/100
Pipeline Concentration
26/100
Pipeline Freshness
60/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Sep 17, 2026
Recruiting
A 10-Year, Postmarketing, Multicenter, Safety Surveillance Study of Lecanemab-irmb for the Treatment of Participants With Alzheimer's Disease in Real-World Clinical Practice (Using Alzheimer's Network for Treatment and Diagnostics [ALZ-NET] Registry Data)
Earlier
Aug 28, 2026TrialAn Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer
Aug 28, 2026TrialAn Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
Aug 25, 2026TrialA Prospective Observational Registry Study to Evaluate the Use and Safety of LEQEMBI in Routine Clinical Practice
Aug 22, 2026TrialA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus
Aug 22, 2026TrialAn Open-Label, Single Dose Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Subjects
Aug 18, 2026TrialA Proof-of-Mechanism, Open-Label, Parallel Group Study With an Open-Label Extension Phase to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease
4 more events
Aug 15, 2026TrialA Phase 1, Open-label, 3-Part Study to Assess Potential Drug-Drug Interactions of E2086 When Coadministered Orally With Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in Healthy Subjects
Aug 14, 2026TrialPost Authorization Registry Study of Patients Treated With LEQEMBI
Aug 8, 2026TrialA First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral E1018 in Healthy Adult Subjects
Jul 24, 2026TrialDevelopment and Validation of Algorithms for Identifying Intracerebral Hemorrhage and Seizures in Patients With Alzheimer's Disease: A Retrospective Database Study Using United States Healthcare Administrative Claims Data
Details
Company Info
Company Overview
$30.0B
Mkt Cap
$5.5B
Revenue
—
Cash
CEOHaruo Naito
Founded1941
Employees10,000
HQTokyo, Japan, Japan
ExchangeOTC:ESALY
Websiteeisai.com
LinkedInCompany Page
Therapeutic Focus
OtherNeurologyNephrologyPsychiatryGastroenterologyRespiratoryOncologyCardiovascularImmunologyRare DiseaseMetabolic & EndocrineOphthalmologyMusculoskeletalHematologyInfectious Disease
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Neurology
Immunology
Neurology
Narcolepsy
E2086Phase 2
Oncology
Unknown / Other
Regulatory
Regulatory Timeline
20204 events
FDADec 18
Lenvima — LENVIMA
Application NDA206947
FDANov 10
Lenvima — LENVIMA
Application NDA206947
FDASep 14
Lenvima — LENVIMA
Application NDA206947
FDAApr 23
Lenvima — LENVIMA
Application NDA206947
20215 events
FDADec 19
Lenvima — LENVIMA
Application NDA206947
FDASep 30
Halaven — HALAVEN
Application NDA201532
FDAAug 10
Lenvima — LENVIMA
Application NDA206947
FDAJul 21
Lenvima — LENVIMA
Application NDA206947
FDAFeb 19
Halaven — HALAVEN
Application NDA201532
20225 events
FDANov 10
Lenvima — LENVIMA
Application NDA206947
FDASep 13
Halaven — HALAVEN
Application NDA201532
FDAAug 5
Lenvima — LENVIMA
Application NDA206947
FDAMar 11
Aricept — ADLARITY
Application NDA212304 (NDA)
FDAMar 11
Aricept — ADLARITY
Application NDA212304 (NDA)
20232 events
FDAOct 23
Lenvima — LENVIMA
Application NDA206947
FDAJan 6
Leqembi — LEQEMBI
Application BLA761269 (BLA)
20243 events
FDANov 20
Lenvima — LENVIMA
Application NDA206947
FDAJun 7
Lenvima — LENVIMA
Application NDA206947
FDAApr 3
Lenvima — LENVIMA
Application NDA206947
20251 event
FDAJan 29
Lenvima — LENVIMA
Application NDA206947
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)